Related Experiment Video

Updated: May 31, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

Michael Abern1, Howard L Kaufman, Kalyan Latchamsetty

  • 1Department of Urology, Rush University Medical Center, Chicago, IL, USA;

Oncotargets and Therapy
|June 22, 2011
PubMed

Insights

Immunotherapy using the modified vaccinia Ankara (MVA) virus expressing 5T4 shows promise for advanced prostate cancer. This review explores the rationale and data for the MVA-5T4 vaccine in treating this malignancy.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Advanced prostate cancer, particularly castration-resistant disease, has limited effective treatment options.
  • Immunotherapy, especially cancer vaccines, is a promising approach due to identified prostate-associated antigens and effective delivery vectors.
  • The modified vaccinia Ankara (MVA) virus is a potent vector for vaccine development.

Purpose of the Study:

  • To review the rationale for utilizing immunotherapy in prostate cancer treatment.
  • To summarize preclinical and clinical data for the MVA-5T4 vaccine (TroVax®) in prostate cancer.

Main Methods:

  • Review of preclinical studies investigating the MVA-5T4 vaccine.
  • Analysis of available clinical trial data for MVA-5T4 in prostate cancer patients.
  • Discussion of the scientific basis for 5T4 as a tumor-associated antigen.

Main Results:

  • The MVA-5T4 vaccine has demonstrated potential in preclinical models for prostate cancer.
  • Early clinical data, though limited, suggest a possible role for MVA-5T4 in prostate cancer therapy.
  • The 5T4 antigen is expressed in various tumor types, including prostate cancer.

Conclusions:

  • Immunotherapy, specifically using the MVA-5T4 vaccine, represents a potential therapeutic strategy for advanced prostate cancer.
  • Further clinical investigation is warranted to establish the efficacy and safety of MVA-5T4 in prostate cancer patients.
  • The development of targeted cancer vaccines like MVA-5T4 offers hope for improved outcomes in castration-resistant prostate cancer.
Keywords:
TroVaxcastration resistanceprostate cancervaccine

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations: